Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aronex Nyotran

Executive Summary

NDA filing for injectable nystatin anticipated in 1999, the company said in announcing the receipt of $5.6 mil. in milestone payments from Abbott Laboratories. The two payments are associated with the completion of patient enrollment and treatment required under the protocol for the Phase III study of Nyotran vs. amphotericin B in patients with presumed fungal infections in the U.S. and Europe. Aronex received a $2.8 mil. milestone payment in November
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS033458

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel